Balsm Alofoq Medical Co. (9620.SR) — Cash flow
Operating, investing, and financing cash flow for Balsm Alofoq Medical Co. — annual and quarterly.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 2↓61.0% | 5↑21.2% | 4↑18.5% | 4 | |
| Depreciation & Amortization | 1↑2.4% | 1↓4.0% | 1↓13.1% | 1 | |
| Deferred Income Tax | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stock-Based Compensation | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes in Working Capital | -7↓1192.7% | -0.53↓176.6% | -0.19↑86.7% | -1 | |
| Accounts Receivable | -5↓2461.1% | -0.19↓128.3% | 0.68↑139.0% | -2 | |
| Inventory | -2↓789.3% | -0.22↑73.8% | -0.82↓17.6% | -0.70 | |
| Accounts Payable | 0.12↑196.0% | -0.12↓245.2% | 0.08↓92.3% | 1 | |
| Other Working Capital | -0.12↓98.1% | -0.06↑54.7% | -0.14↓36.1% | -0.10 | |
| Other Non-Cash Items | 0.78↑523.0% | -0.18↓178.0% | 0.24↓81.3% | 1 | |
| Net Cash from Operating Activities | -3↓153.7% | 5↑1.3% | 5↑14.7% | 5 | |
| Operating Cash Flow | -3↓153.7% | 5↑1.3% | 5↑14.7% | 5 | |
| Investing Activities | |||||
| Investment in Property, Plant & Equipment | -4↓1870.4% | -0.21↑97.1% | -7↓3599.6% | -0.19 | |
| Capital Expenditure | -4↓1870.4% | -0.21↑97.1% | -7↓3599.6% | -0.19 | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | |
| Purchases of Investments | 0.00 | 0.00 | 0.00 | 0.00 | |
| Sales & Maturities of Investments | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Cash from Investing Activities | -4↓1870.4% | -0.21↑97.1% | -7↓3599.6% | -0.19 | |
| Financing Activities | |||||
| Net Debt Issuance | 0.00↑100.0% | -0.36↓10.9% | -0.32↑3.0% | -0.33 | |
| Long-Term Net Debt Issuance | 0.00↑100.0% | -0.36↓10.9% | -0.32↑3.0% | -0.33 | |
| Short-Term Net Debt Issuance | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Stock Issuance | 0.00↓100.0% | 13 | 0.00 | 0.00 | |
| Net Common Stock Issuance | 0.00↓100.0% | 13 | 0.00 | 0.00 | |
| Common Stock Issuance | 0.00↓100.0% | 13 | 0.00 | 0.00 | |
| Share Buybacks | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Preferred Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends Paid | 0.00↑100.0% | -3↓212.4% | -0.96 | 0.00 | |
| Common Dividends Paid | 0.00↑100.0% | -3↓212.4% | -0.96 | 0.00 | |
| Preferred Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Financing Activities | -0.31 | 0.00↓100.0% | 0.96↑166.8% | -1 | |
| Net Cash from Financing Activities | -0.31↓103.3% | 9↑3004.7% | -0.32↑81.9% | -2 | |
| Cash Reconciliation | |||||
| Effect of Foreign Exchange | 0.00 | 0.00 | 0.00↓100.0% | 3 | |
| Net Change in Cash | -7↓150.8% | 15↑807.0% | -2↓135.9% | 6 | |
| Cash at Beginning of Period | 18↑396.0% | 4↓35.9% | 6 | 0.00 | |
| Cash at End of Period | 11↓40.6% | 18↑396.0% | 4↓35.9% | 6 | |
| Income Taxes Paid | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Paid | 0.00 | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | -7↓234.6% | 5↑402.9% | -2↓138.5% | 5 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.